Liquidia Technologies has announced the appointment of AbbVie VP of Global Commercial Development Katie Rielly-Gauvin to its board of directors for a term that will extend until company’s 2020 annual meeting. Prior to her position at AbbVie, Rielly-Gauvin held various executive positions at Johnson & Johnson companies over a number of therapeutic areas.
In March 2019, Liquidia announced that a Phase 3 trial of its LIQ861 inhaled treprostinil for the treatment of pulmonary arterial hypertension met its primary endpoint. The company also announced in June 2019 that it plans to develop several additional inhalation products based on its PRINT particle manufacturing technology.
Liquidia Chairman of the Board Stephen Bloch commented, “Adding Katie to our board is another significant step in preparing Liquidia for commercial growth. Not only does her commercial experience have a direct bearing on our pre- and post-launch considerations for LIQ861, but it also increases the breadth of therapeutic area expertise from which the company may draw.”
Rielly-Gauvin said, “I am honored to be joining the Liquidia team at this pivotal time in preparing for commercial success of its first potential product. While the advantages of LIQ861 are clear for pulmonary arterial hypertension (PAH) patients, the potential applications of PRINT technology expand beyond the inhaled route of delivery. I look forward to working with the board and management to help create a portfolio of products that address unmet medical needs.”
Read the Liquidia Technologies press release.
